[A21-166] Ozanimod (ulcerative colitis) - Benefit assessment according to §35a Social Code Book V
Last updated 20.05.2022
Project no.:
A21-166
Commission:
Commission awarded on 14.12.2021 by the Federal Joint Committee (GBA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Digestion, metabolism and hormones
Adults with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or are intolerant to either conventional treatment or a biologic drug
- Patients who have had an inadequate response with, lost response to, or have intolerance or contraindications to conventional treatment: added benefit not proven
- Patients who have had an inadequate response with, lost response to, or are intolerant to treatment with a biologic drug (TNFα antagonist or integrin inhibitor or interleukin inhibitor): added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
The current version 2.0 of the dossier assessment replaces version 1.0 published on 2022-03-15.
| Project no. | Title | Status |
|---|---|---|
| A20-59 | Ozanimod (relapsing remitting multiple sclerosis) - Benefit assessment according to §35a Social Code Book V | Commission completed |